Accelerating Precision Medicine with Rapid Front-Line NGS
Event Name: AMP 2025
TBC
Laboratory Validation of Pillar’s onocoReveal Myeloid Panel on the Illumina MiSeq i100 to Deliver Rapid Front-Line NGS for Heme Malignancies
Event Name: AMP 2025
TBC
Rapid Detection of Actionable Biomarkers in Liquid Biopsy from Non-Small Cell Lung Cancer and Breast Cancer Using Targeted NGS-Based Assays
Event Name: AMP 2025
TBC
Pillar Biosciences Enables Rapid, Localized Tumor Profiling of Lymphoid Malignancies with Launch of New Kitted NGS Panel
NATICK, Mass. – November 11, 2025– (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories to perform rapid tumor profiling of lymphoid malignancies. The oncoReveal Lymphoid panel interrogates 84 genes of interest, including full coding […]